eShowcase: QUMAS Compliance Closed-Loop Process
System treats compliance as a single, repeatable process to ensure organizational quality
System treats compliance as a single, repeatable process to ensure organizational quality
QUMAS (Florham Park, NJ) has released an end-to-end closed-loop compliance solution for life science companies. The QUMAS Compliance Closed-Loop Process™, which the company says is the first product of its kind in the industry, automates the tracking and management of compliance, business, and quality issues enterprise-wide.
The solution integrates various tasks with other processes critical to regulatory compliance. Rather than treating compliance as a series of silos that vary with department and/or product lifecycle stage, the Compliance Closed-Loop Process treats it as a single procedure.
The QUMAS approach automates the generation of internal or external complaints, product nonconformances, deviations, audits, investigations, and all other compliance actions. The tool captures, records, routes, and verifies completion and approvals while auditing each step in a sponsor's quality management process.
QUMAS, (800) 577-1545, www.qumas.com
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
